Welcome to our dedicated page for Intellia Therape SEC filings (Ticker: NTLA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Intellia Therapeutics, Inc. filings document the business, governance and capital structure of a Nasdaq-listed clinical-stage biopharmaceutical company developing CRISPR-based therapies. Its Form 8-K reports record quarterly financial results and business updates, clinical and regulatory disclosures for lonvo-z in hereditary angioedema, nex-z in ATTR amyloidosis, and related FDA communications.
The filing record also includes common stock financing disclosures, including an underwritten public offering and amendments to an at-the-market sales program. Proxy materials describe annual meeting matters, executive compensation, equity awards and board governance, while bylaw amendments and other corporate filings address shareholder proposal procedures, forum provisions and registered common stock listed on The Nasdaq Global Market.
Intellia Therapeutics reported additional positive Phase 3 data from its global HAELO trial of lonvoguran ziclumeran (lonvo-z) for hereditary angioedema. The study previously met its primary endpoint, showing an 87% reduction in mean monthly attacks in the lonvo-z arm versus placebo during weeks 5 to 28. In that period, 62% of lonvo-z patients were attack free and therapy free compared with 11% on placebo. New key secondary data showed the mean monthly rate of attacks requiring on-demand treatment was 0.19 in the lonvo-z arm versus 1.79 on placebo, an 89% reduction. All treatment-emergent adverse events in the lonvo-z arm were mild or moderate, with no serious adverse events observed. Intellia has initiated a rolling biologics license application for lonvo-z with the FDA and continues to anticipate regulatory approval and a U.S. launch in the first half of 2027.
Intellia Therapeutics director Frank Verwiel received new equity awards. He was granted 9,200 restricted stock units, each representing a contingent right to receive one share of Intellia common stock. Following this grant, he holds 35,148 common shares directly.
He was also awarded a stock option for 13,300 shares of common stock at an exercise price of $12.89 per share. This option vests in full on the earlier of the first anniversary of the June 9, 2026 grant date or the next annual meeting of stockholders, and expires on June 8, 2036.
Intellia Therapeutics director Georgia Keresty received equity compensation in the form of restricted stock units and stock options. She acquired 9,200 shares of common stock at no cost through a grant of restricted stock units, bringing her direct holdings to 41,083 shares.
Keresty was also granted stock options covering 13,300 shares of common stock at an exercise price of $12.89 per share. According to the terms, this option vests in full on the earlier of the first anniversary of the June 9, 2026 grant date or the next annual meeting of stockholders following the grant date.
Intellia Therapeutics, Inc. director Jesse Goodman reported equity awards consisting of common stock and stock options as part of compensation. He received 9,200 shares of Common Stock$0.00 per share33,559 shares
Goodman also received a stock option for 13,300 shares of Common Stock$12.89 per share13,300 shares
Intellia Therapeutics director Brian Goff received new equity compensation awards. He was granted 9,200 restricted stock units, each representing one share of common stock, and stock options covering 13,300 shares at an exercise price of $12.89. Following the grant, he directly holds 32,609 common shares, and the options vest in full on the earlier of one year from grant or the next annual stockholder meeting.
Intellia Therapeutics, Inc. director Fred E. Cohen received new equity-based compensation. He was granted 9,200 restricted stock units, each representing a contingent right to one share of Intellia common stock, increasing his direct common stock holdings to 216,653 shares.
He was also granted a stock option covering 13,300 shares of common stock at an exercise price of $12.89 per share. This option vests in full on the earlier of the first anniversary of the June 9, 2026 grant date or the next annual meeting of stockholders, and expires on June 8, 2036.
Intellia Therapeutics director William J. Chase received new equity awards. On June 9, he was granted 9,200 restricted stock units, each representing the right to receive one share of Intellia common stock upon vesting.
He also received a stock option covering 13,300 shares of common stock at an exercise price of $12.89 per share. This option vests in full on the earlier of the first anniversary of the grant date or the next annual stockholders’ meeting. After the RSU grant, Chase directly holds 143,893 common shares.
Intellia Therapeutics director Muna Bhanji received new equity awards. She was granted 9,200 shares of common stock based on restricted stock units, bringing her direct common stock holdings to 36,403 shares.
She was also granted stock options for 13,300 shares at an exercise price of $12.89 per share. These options vest in full on the earlier of the first anniversary of the June 9, 2026 grant date or the next annual meeting of stockholders, and expire on June 8, 2036.
Intellia Therapeutics, Inc. reported the results of its Annual Meeting of stockholders held on June 9, 2026. Stockholders voted on three proposals that had been described in the company’s Proxy Statement.
For the election of directors, Muna Bhanji received 57,065,465 votes for and 1,610,941 against, Brian Goff received 46,090,644 for and 12,582,130 against, and Jesse Goodman received 43,004,221 for and 15,686,289 against, each with additional abstentions and 30,124,178 broker non-votes. A separate proposal received 87,833,534 votes for, 779,540 against, and 249,592 abstentions, with no broker non-votes. Another proposal received 44,806,637 votes for, 13,821,404 against, 110,447 abstentions, and 30,124,178 broker non-votes. No other matters were submitted to stockholders.